This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ooi, T. C. Articles by Simo, I. E. Search for Related Content PubMed PubMed Citation Articles by Ooi, T. C. Articles by Simo, I. E.

Postprandial Remnant-like Lipoproteins in Hypertriglyceridemia¹

From the Metabolism and Hormone Laboratory (T.C.O., M.C., D.S.O., I.E.S.), Division of Endocrinology and Metabolism, and Division of Biochemistry (T.C.O., D.S.O.), Department of Laboratory Medicine, Ottawa Hospital–Civic Campus, University of Ottawa, Ottawa, Ontario, Canada K1Y 4E9; Division of Endocrinology and Metabolism (G.S., K.D.U.), Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada M5G 1L7; and Otsuka America Pharmaceutical, Inc. (K.N.), Rockville, Maryland 20850

Address all correspondence and requests for reprints to: Dr. T. C. Ooi, Division of Endocrinology and Metabolism, Ottawa Hospital–Civic Campus 1053, Carling Avenue, Ottawa, Ontario, Canada K1Y 4E9. E-mail: tcooi{at}ottawahospital.on.ca

Abstract

It has been proposed that remnants of chylomicrons and very-low-density lipoproteins (VLDL) are atherogenic. We have used an immunochemical method to isolate remnant-like particles (RLP) and measured them in terms of their cholesterol and triglycerides (TG). RLP consist of apoB-48-containing triglyceride-rich lipoproteins and remnant-like VLDL containing apoB-100. The study aim was to look for information from postprandial RLP data that could not be known from other markers of triglyceride-rich lipoproteins and fasting TG and RLP data alone. A total of 41 subjects were studied. Eight subjects had hypertriglyceridemia (HTG) and low high-density lipoprotein (HDL), 14 had combined hyperlipidemia (CH), 5 had the apo E2/2 genotype receiving gemfibrozil, 10 were normolipidemic (NL) controls, and 4 had hypercholesterolemia. As a whole group, there was correlation among 1) fasting TG, RLP cholesterol (RLP-C), and RLP-TG but not VLDL apo B100, VLDL apo B48 and their respective postprandial responses measured as incremental area under the curve (IAUC), 2) fasting TG and postprandial IAUC of RLP-C and RLP-TG, 3) RLP-C IAUC, RLP-TG IAUC, and TG IAUC, retinyl palmitate (RP) IAUC, and VLDL apo B48 IAUC but not VLDL apo B100 IAUC. The HTG/low HDL-C and CH groups had higher IAUC for RLP-C, RLP-TG, TG, and RP than the NL group. Fasting and postprandial RLP were triglyceride enriched in the HTG/low HDL-C group and to a lesser extent in the CH group. The HTG/low HDL-C and CH groups had a delay in their RLP-C but not RLP-TG peaks suggesting a delay in hepatic clearance of RLP and/or a protracted period of lipolysis and/or processing of RLP. The fasting and postprandial RLP-C/RLP-TG and RLP-C/TG ratios were elevated in the apo E2/2 group in spite of gemfibrozil therapy. The increment in postprandial RLP was, however, not exaggerated. Our data indicate that 1) postprandial RLP lipemia is enhanced in HTG subjects when compared with NL subjects, 2) postprandial RLP lipemia is proportional to fasting RLP and TG levels and mirrors, to a large extent, increases in postprandial TG, RP, and VLDL apo B48 but not VLDL apo B100, 3) there are compositional differences in fasting and postprandial RLP in the three forms of HTG studied, RLP being triglyceride enriched in the HTG/low HDL-C group and to a lesser extent in the CH group, and cholesterol-enriched in the apo E2/2 group, and 4) apo E2/2 subjects had high fasting and postprandial RLP-C concentrations in spite of being on treatment with gemfibrozil and having normal fasting and postprandial TG concentrations.

This article has been cited by other articles:

				R. S. Rosenson, D. A. Wolff, A. L. Huskin, I. B. Helenowski, and A. W. Rademaker Fenofibrate Therapy Ameliorates Fasting and Postprandial Lipoproteinemia, Oxidative Stress, and the Inflammatory Response in Subjects With Hypertriglyceridemia and the Metabolic Syndrome Diabetes Care, August 1, 2007; 30(8): 1945 - 1951. [Abstract] [Full Text] [PDF]

				A. C. Ferreira, A. A. Peter, A. J. Mendez, J. J. Jimenez, L. M. Mauro, J. A. Chirinos, R. Ghany, S. Virani, S. Garcia, L. L. Horstman, et al. Postprandial Hypertriglyceridemia Increases Circulating Levels of Endothelial Cell Microparticles Circulation, December 7, 2004; 110(23): 3599 - 3603. [Abstract] [Full Text] [PDF]

				G. D. Kolovou, D. Ch. Daskalova, S. A. Iraklianou, E. N. Adamopoulou, N. D. Pilatis, G. C. Hatzigeorgiou, and D. V. Cokkinos Postprandial Lipemia in Hypertension J. Am. Coll. Nutr., February 1, 2003; 22(1): 80 - 87. [Abstract] [Full Text] [PDF]

				M. Guerin, P. Egger, W. Le Goff, C. Soudant, R. Dupuis, and M. J. Chapman Atorvastatin Reduces Postprandial Accumulation and Cholesteryl Ester Transfer Protein-Mediated Remodeling of Triglyceride-Rich Lipoprotein Subspecies in Type IIB Hyperlipidemia J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 4991 - 5000. [Abstract] [Full Text] [PDF]